Receptor activity‐modifying protein‐dependent impairment of calcitonin receptor splice variant Δ(1–47)hCT(a)function
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Alternative splicing expands proteome diversity to GPCRs. Distinct receptor variants have been identified for a secretin family GPCR, the calcitonin receptor (CTR). The possible functional contributions of these receptor variants are further altered by their potential interactions with receptor activity‐modifying proteins (RAMPs). One variant of the human CTR lacks the first 47 residues at its N terminus [Δ(1–47)hCT(a)]. However, very little is known about the pharmacology of this variant or its ability to interact with RAMPs to form amylin receptors. Experimental Approach: Δ(1–47)hCT(a)was characterized both with and without RAMPs in Cos7 and/or HEK293S cells. The receptor expression (ELISA assays) and function (cAMP and pERK1/2 assays) for up to six agonists and two antagonists were determined. Key Results: Despite lacking 47 residues at the N terminus, Δ(1–47)hCT(a)was still able to express at the cell surface, but displayed a generalized reduction in peptide potency. Δ(1–47)hCT(a)retained its ability to interact with RAMP1 and formed a functional amylin receptor; this also appeared to be the case with RAMP3. On the other hand, its interaction with RAMP2 and resultant amylin receptor was reduced to a greater extent. Conclusions and Implications: Δ(1–47)hCT(a)acts as a functional receptor at the cell surface. It exhibits altered receptor function, depending on whether it associates with a RAMP and which RAMP it interacts with. Therefore, the presence of this variant in tissues will potentially contribute to altered peptide binding and signalling, depending on the RAMP distribution in tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299 · cited 1×
“Amy was initially discovered in amyloid deposits of human insulinoma and the pancreas of type 2 diabetic patients (Cooper et al., 1987).”
BackgroundPoyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.233 · Cited by 804 · cited 3×
“This is consistent with the pharmacology of receptor complexes, where RAMPs 1 and 3 tend to support higher affinity CGRP interactions than RAMP2 (Poyner et al., 2002; Gingell et al., 2010; Moore et al., 2010). rAmy potency was affected most in RAMP2 complexes.”
BackgroundChristopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486
Morfis, M., Tilakaratne, N., Furness, S. G. B., Christopoulos, G., Werry, T. D., Christopoulos, A., & Sexton, P. M. (2008) · Endocrinology · doi:10.1210/en.2007-1735 · Cited by 134 · cited 1×
“It has previously been reported that the same CTR/RAMP complexes exhibit different signalling profiles in different cellular backgrounds, likely due to the expressed complement of proteins that is unique to each cell type (Morfis et al., 2008).”
BackgroundHilton, J., Dowton, M., Houssami, S., & Sexton, P. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1660213 · Cited by 70 · cited 1×
“This apparently contradicts the full-length sCT data but sCT is a very potent/ high affinity agonist that elicits poor reversibility of binding to human CTR; on the other hand, antagonists including CT8–32 bind reversibly to the receptor (Hilton et al., 2000; Poyner et al., 2002).”
BackgroundFindlay, D. M., & Sexton, P. M. (2004) · Growth Factors · doi:10.1080/08977190410001728033 · Cited by 54
Cited by
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Self-citationCGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Self-citationBower, R. L., & Hay, D. L. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13496 · Cited by 104
Self-citationWeston, C., Winfield, I., Harris, M., Hodgson, R., Shah, A., Dowell, S. J., Mobarec, J. C., Woodlock, D. A., Reynolds, C. A., Poyner, D. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.751362 · Cited by 95
Self-citation
Metadata
- Authors
- Qi, T., Dong, M., Watkins, H., Wootten, D., Miller, L., & Hay, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-01-16
- Volume
- 168
- Issue
- 3
- Pages
- 644-657
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1491382381
- Cited by
- 47
- References
- 6
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Receptor activity‐modifying protein‐dependent impairment of calcitonin receptor splice variant Δ(1–47)hCT(a)function. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.02197.x
- The paper
- Qi, T., Dong, M., Watkins, H., Wootten, D., Miller, L., & Hay, D. (2013). Receptor activity‐modifying protein‐dependent impairment of calcitonin receptor splice variant Δ(1–47)hCT(a)function. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.02197.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.